



# Bharat Parenterals Limited

**Registered Office & Works:**

Survey No.: 144-A, Jarod-Samlaya Road, Vill. Haripura,  
Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Mobile : 99099 28332

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: L24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

Date: 13th March, 2024

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai -400 001  
Scrip Code: 541096

Dear Sir / Madam,

**SUBJECT:- GENERAL ANNOUNCEMENT AS PER SEBI LODR, 2015 UPDATE ABOUT COMPANY.**

In compliance of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform -

**BHARAT PARENTERALS SUBSIDIARY INNOXEL LIFESCIENCES BAGGED ITS FIRST MILESTONE DEAL OF RS 31 CR.**

On 13th March 2024, Bharat Parenterals's subsidiary Innoxel Lifesciences has signed a deal to out license seven complex molecules including two, 505(b) 2 products with two Global Complex Generic marketing companies. According to agreement, Innoxel Lifesciences will receive cumulative milestone payments of Rs. 31 Cr over the period of next three years (Rs 10.3 cr every year). Primary countries for Marketing will be United States and some of the European countries.

Innoxel Lifesciences has developed total twenty-two complex generic molecules, including seven 505(b) 2. Additional sixteen molecules are in pipeline and likely to be developed over the next two years. Innoxel Lifesciences has a state-of-the-art manufacturing facility with SKID based technology in Vadodara to manufacture these drugs. On successful filing and approval of these molecules, company will manufacture drugs on contract manufacturing basis and will also receive Profit Share income after commercialisation in the future.

Bharat Parenterals Limited's headquarter is based out of Vadodara, Gujarat. They manufacture and market high-quality pharmaceutical formulations for the global market. Bharat Parenterals is one of the leading players in injectables dosage form with a large portfolios and production capacities in this segment, with a vision of making world class affordable drugs. Innoxel Lifesciences was incorporated in the year 2021 with the vision of developing and manufacturing of highly complex generic molecules, including 505(b)2 for the regulated markets, mainly the United States and select Western European countries.

**FOR BHARAT PARENTERALS LIMITED**

.....  
**Krutika Bhattbhatt**  
**Company Secretary**

